CTLA4 and renal cell carcinoma: In patients with advanced RCC, the combination of ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody) was compared with the previous sunitinib (VEGF-TKI), resulting in a significant improvement in treatment.